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Background: It has not been fully evaluated whether both HER2
gene copy number and HER2 protein expression are related to the
outcome of chemoradiotherapy in patients with locally advanced
non-small cell lung cancer (LA-NSCLC). The aim of this study was
to evaluate their relationships.
Methods: HER2 gene copy number determined by fluorescence in
situ hybridization (FISH) and HER2 protein expression determined
by immunohistochemistry (IHC) were assessed in 68 patients with
LA-NSCLC enrolled in our previous phase II trials of concurrent
cisplatin-based chemoradiotherapy, and a multivariate analysis was
conducted for response and survival.
Results: HER2-IHC-positive tumors were detected in 23 patients
(34%), and the median ratio of HER2 to chromosome 17 copy
number was 0.93 (range, 0.55–2.00). The HER2-FISH results were
marginally correlated with the IHC results (p  0.0715). When the
median ratio in the FISH analysis was used as a cut-off level for its
positivity, there was no association between either HER2-FISH or
IHC status and objective response to chemoradiotherapy. Contrary,
a multivariate analysis revealed HER2-FISH result but not IHC
result was an independent poor prognostic factor for both overall
survival and progression-free survival (hazard ratio  2.568, 95%
confidence interval [CI]  1.117–5.903, p  0.0264 and hazard
ratio  2.283, 95% CI  1.005–5.189, p  0.0487, respectively).
Conclusions: Patients with HER2 FISH-positive LA-NSCLC had a
poorer outcome even when treated with cisplatin-based chemora-
diotherapy, despite the strong need for validation assessment of
these observations. Development of more effective treatment for
these high-risk patients is needed to improve their poor prognosis.
Key Words: Locally advanced non-small cell lung cancer, HER2/
neu, FISH, Prognosis.
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Locally advanced non-small cell lung cancer (LA-NSCLC)is characterized by widespread primary tumor and/or ex-
tensive nodal involvement, and improving the clinical out-
come of LA-NSCLC is one of the major challenges for medical
oncologists. Based on randomized controlled trials,1,2 cisplatin-
based chemotherapy and concurrent thoracic irradiation is now
considered the standard treatment for LA-NSCLC, and it has
yielded a response rate of 80%. Nevertheless, despite the initial
response, the majority of patients experience recurrence, and the
5-year survival rate is still around 20%. As a first step in improving
the unsatisfactory treatment outcome it would seem reasonable to
select LA-NSCLC patients who would benefit least from the stan-
dard treatment consisting of cisplatin-based chemotherapy and con-
current thoracic irradiation and then develop novel treatment strat-
egies for this high-risk patient population.
HER2/neu is tyrosine kinase receptor having a molec-
ular weight of 185,000 and is a member of the ErbB protein
family. HER2/neu signaling is known to be associated with
the proliferation and survival of cancer cells, and it is over-
expressed in a variety of tumors, including breast cancer and
NSCLC.3 HER2 overexpression has been reported to be
associated with resistance to both radiation and chemothera-
peutic agents, including cisplatin and 5-fluorouracil, in pre-
clinical studies.4,5 Indeed, in several clinical studies of locally
advanced cancers, including breast, esophageal, and head and
neck cancers, combined modality treatment consisting of
systemic chemotherapy and irradiation has been found to be
less effective in patients whose tumors overexpress HER2
than in patients whose tumors do not.6–8
Patient survival is undoubtedly the principal goal of
chemoradiotherapy, but the role of HER2 protein expression
determined by immunohistochemistry (IHC) in the survival
of NSCLC patients has long been a matter of controversy.
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Two recent meta-analyses have shown a significant associa-
tion between HER2 protein overexpression and poor outcome
in NSCLC patients.9,10 Nevertheless, it seems problematic
that the analyses included very heterogeneous studies, with
various disease stages, various treatments, and different meth-
odologies for assessment of HER2 status in each study. In
addition, it has not yet been determined whether the association
holds for LA-NSCLC, because the meta-analyses rarely in-
cluded relevant studies of LA-NSCLC.
Regarding HER2 gene copy number, fluorescence in situ
hybridization (FISH) is another commonly used method of
determining the HER2 status of tumors, and its clinical useful-
ness for predicting survival has been extensively evaluated,
mainly in breast cancer.11 Nevertheless, few studies have for-
mally assessed the association in an LA-NSCLC setting, and the
aforementioned meta-analyses included hardly any studies that
assessed HER2 gene amplification status and patient out-
come.9,10 Thus, in this study, we investigated the association
between both HER2-FISH status and high HER2 protein levels
and the clinical outcome of LA-NSCLC patients by using the
long-term follow-up data sets of two prospective phase II studies
that we conducted to evaluate the efficacy of cisplatin-based
concurrent chemoradiotherapy against LA-NSCLC.
MATERIALS AND METHODS
Patients and Treatment
This study was a laboratory companion study to the two
phase II concurrent chemoradiotherapy studies for locally
advanced unresectable stage IIIA and IIIB NSCLC conducted
by the Okayama Lung Cancer Study Group (OLCSG) be-
tween January 1994 and December 1999. The details of these
prospective studies have already been reported.12,13 In brief,
both studies had similar eligibility criteria: pathologically
confirmed NSCLC, previously untreated disease, measurable
lesions, age 75 years, and IIIA or IIIB clinical stage. Institu-
tional review boards approved the study protocols, and the
patients provided written informed consent. Mediastinoscopy
was not included in the staging work-up examination. Treatment
in the first study (OLCSG 9404) consisted of three cycles of
5-fluorouracil (500 mg/m2, days 1–5) and cisplatin (20 mg/m2,
days 1–5) every 4 weeks, and concurrent hyperfractionated
radiotherapy (1.25 Gy twice daily, total dose: 62.5–70 Gy). In
the second study (OLCSG 9707), treatment comprised a com-
bination of docetaxel 40 mg/m2 and cisplatin 40 mg/m2 given on
days 1, 8, 29, and 36 with concurrent radiotherapy (2 Gy daily,
total 60 Gy). Patients from whom appropriate tumor specimens
for the molecular analyses with providing informed consents had
been obtained were included in this study.
FISH and Immunohistochemistry
Sections from paraffin-embedded tissue blocks containing
representative malignant cells prepared from tissue obtained at
the time of diagnosis were used for the FISH and IHC analyses.
The level of HER2 protein expression was determined by IHC
using the Dako Herceptest kit (DAKO, Copenhagen, Den-
mark).14 Staining was performed according to the protocol
described in the manufacturer’s guide. Membrane staining in-
tensity and patterns were evaluated by using the 0 to 3 scale
according to the HercepTest kit scoring guidelines. Scores of 0
or 1 were considered negative for HER2 overexpression, a
score of 2 was considered weakly positive, and a score of 3
was considered strongly positive. To qualify for 2 and 3
scoring, complete membrane staining of more than 10% of
tumor cells had to be observed. The results were reported
as negative (score 0 to 1) or positive (score 2 to 3).
Dual-target, dualcolor FISH assays were performed using
the PathVysion HER-2 DNA probe kit (Vysis/Abbott Labora-
tories, Downers Grove, IL), which includes the LSI HER-2
SpectrumOrange and the CEP 17 SpectrumGreen probes, as
described elsewhere.15 The reference slide (stained with hema-
toxylin and eosin) was the section adjacent to the section on
which the dominant tumor focus had been identified, and the
copy numbers of the HER2 gene and chromosome 17 centro-
mere probes were assessed and recorded independently in at
least 100 nonoverlapping nuclei with intact morphology while
constantly refocusing the microscope to detect signals located on
different focal planes. The results were reported as negative or
positive with the median ratio of HER2 to chromosome 17 copy
numbers as the cut-off value.
All molecular analyses were performed independently by
2 observers (S.K. and M.T.) blinded to the patients’ clinical
information, and discrepant scores were resolved by consensus.
Radiologic Evaluation and Statistical Analysis
Responses were assessed by using the World Health
Organization criteria for OLCSG 9404 and by using Eastern
Cooperative Oncology Group criteria for OLCSG 9707. The
response to treatment was determined for each patient by
extramural reviewers. The Mann-Whitney U test and 2 or
Fisher exact test were used for comparisons among groups.
The relationship between HER2 status and response was
assessed by logistic regression analysis with adjustment for
the impact of the following potential confounders: HER2-
FISH status, HER2-IHC status, nodal metastasis (N3 versus
others), age (70 versus 70), histology (squamous cell
carcinoma versus others), chemotherapy regimens (cisplatin
and docetaxel versus cisplatin and 5-fluorouracil), and pre-
treatment performance status (0 versus 1 or worse). Progres-
sion-free survival time was defined as the interval between
the start of therapy and the day of documented disease
progression or any deaths. Overall survival time was defined
as the interval between the start of chemoradiotherapy and the
time of death from any cause or the most recent date the
patient was known to be alive. The survival curves were
constructed by the Kaplan-Meier product-limit method. Dif-
ferences between the curves were evaluated by the log-rank
test. Proportional hazard regression models were used to
evaluate the above confounding factors. All p-values were
two-sided, and significance was set at a p value of 0.05.
RESULTS
Patient Characteristics, Response, and Survival
Because tumor samples were available for 40 (80%) of
the 50 patients enrolled for the cisplatin and 5-fluorouracil
regimen and for 28 (67%) of the 42 patients enrolled for the
cisplatin and docetaxel regimen, a total of 68 patients were
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included in this study (Table 1). The majority of the patients
were male (87%) and had stage IIIB disease (76%).
An objective response to therapywas observed in 45 (66.2%)
patients. The 5-year overall survival rate, median survival time, and
median progression-free survival time were 33.8%, 24.0 months,
and 12.2months, respectively, and themedian follow-up time in the
surviving patients was 87.8 months.
Correlation Between the IHC Results and the
FISH Results
According to the HercepTest kit scoring guidelines, 45
(66%), 16 (24%), and 7 (10%) of the tumors were scored 0 to
1, 2, and 3, respectively. The results of the FISH
analysis yielded a median ratio of HER2 to chromosome 17
copy numbers of 0.93 (range, 0.55–2.00) that was used as a
cut-off value for the FISH positivity in this study.
We investigated the relationship between HER2 copy
number and HER2 protein expression, because it is still the
subject of controversy in NSCLC.16,17 The ratios of HER2 to
chromosome 17 copy numbers were higher in the patients
with high HER2-IHC scores (2 to 3) than in those with
low scores (0 to 1) (median ratio: 0.89 and 0.97, respec-
tively; Mann-Whitney U test; p  0.0715; Figure 1).
Relation of HER2 Status to Response and Outcome
Neither HER2-FISH nor IHC statuses were associated
with objective response to the chemoradiotherapy with the
objective response rates of 68.2% versus 54.5% in FISH-
positive and negative tumors, and 65.2% and 66.7% in
HER2-protein positive (score 2 to 3) and negative (score
0 to 1) tumors, respectively. Regarding overall survival,
patients with HER2-FISH-positive tumors had a poorer out-
come than those with FISH-negative tumors, despite the
absence of a statistically significant difference (log-rank test;
p  0.1352), and they had a 5-year overall survival rate of
22.7% and 40.9%, respectively, and a median survival time of
15.5 months and 29.7 months, respectively (Figure 2A). The
multivariate analysis revealed that HER2-FISH status was an
independent prognostic factor for poor overall survival (haz-
ard ratio [HR]  2.568, 95% confidence interval [CI] 
1.117–5.903, p  0.0264; Table 2). In addition, progression-
free survival was different in patients with and without
HER2-FISH-positive tumors in the univariate analysis (me-
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FIGURE 1. Association between the HER2 immunohisto-
chemistry (IHC) and fluorescence in situ hybridization (FISH)
assay results. The FISH results were expressed as the ratio of
HER2 to chromosome 17 copy number in each patient. The
IHC results were divided into two categories according to
the HercepTest kit scoring guidelines: negative (score 0 to
1) and positive (score 2 to 3).
TABLE 1. Clinical Background of the 68 Patients
Age (yr, median range) 65 (29–75)
Gender (male/female) 59 (87%)/9 (13%)
PS (0/1/2)a 26 (38%)/41 (60%)/1 (1%)
Histology (Sq/Ad/others) 30 (44%)/28 (41%)/10 (15%)
Stage (IIIA/IIIB) 16 (24%)/52 (76%)
Nodal metastasis (N1/N2/N3) 8 (12%)/42 (62%)/18 (26%)
Protocol regimens (#9404 vs. #9707)b 28 (41%)/40 (59%)
a Eastern Cooperative Oncology Group performance status.
b Combination chemotherapy with concurrent thoracic irradiation (cisplatin and 5-flu-
orouracil regimen in the Okayama Lung Cancer Study Group Protocol 9404) and cisplatin
and docetaxel regimen in the Okayama Lung Cancer Study Group Protocol 9707).
Ad, adenocarcinoma; Sq, squamous cell carcinoma; PS, performance status.
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FIGURE 2. Survival curves stratified by HER2-fluorescence in
situ hybridization (FISH) results. Bold and nonbold lines rep-
resent patients with positive and negative FISH results, re-
spectively. A, Overall survival Curves (5-year overall survival
rate and median survival time of patients with HER2-FISH
positive and negative tumors of 22.7% and 40.9%, respec-
tively, and 15.5 months and 29.7 months, respectively; log-
rank test; p  0.1352). B, Progression-Free survival Curves
(median progression-free survival times of 10.0 months and
14.1 month in those with the positive and negative HER2-
FISH results, respectively, log-rank test; p  0.0871).
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dian progression-free survival time of 10.0 months and 14.1
month, respectively, log-rank test; p  0.0871; Figure 2B)
and in the multivariate analysis (HR  2.283, 95% CI 
1.005–5.189, p  0.0487; Table 2). Nevertheless, there was
no significant association between HER2-IHC status and
either overall survival or progression-free survival (Table 2
and Figures 3A, B).
DISCUSSION
This is the first study to show a significant correlation
between HER2-FISH status and both progression-free survival
and overall survival of LA-NSCLC patients after the start of
cisplatin-based concurrent chemoradiotherapy. The results of
this study showed that HER2-FISH-positive tumors are very
aggressive even when treated with the current standard chemo-
radiotherapy (HR for overall survival and median progression-
free survival of 2.568 [95% CI 1.117–5.903] and 2.283 [95%
CI 1.005–5.189], respectively). In addition, since LA-NSCLC
patients constitute a heterogeneous population, it seems impor-
tant to select these patients stratified by HER2-FISH status, and
investigate and develop novel treatment strategies especially for
those expected to have a poor outcome even if treated by
standard chemoradiotherapy.
No previous studies have evaluated the role of HER2-
FISH in the survival of LA-NSCLC patients after chemoradio-
therapy, although HER2-FISH is associated with treatment out-
come neither in patients with more advanced NSCLC receiving
chemotherapy alone,18 nor in resected patients with early dis-
ease.17 The differences in results between previous studies and
our own may be attributable to the selection of patients with
different disease stages, differences in treatments and differences
in definition of HER2-FISH-positive.
We used the frequently used definition of HER2-positive
in the HercepTest kit scoring guidelines and failed to find any
association between HER2-IHC status and outcome. Previous
studies reported similar results in LA-NSCLC patients treated
with combination therapy consisting of thoracic irradiation and
cisplatin-based chemotherapy.19,20 Some studies in breast cancer
have demonstrated that IHC does not consistently discriminate
patients likely to have a poor outcome, whereas FISH provides
superior prognostic information for segregating high-risk from
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FIGURE 3. Survival curves stratified by HER2-FISH results.
Bold and nonbold lines represent patients with HER2-protein
positive (score 2 to 3) and negative (score 0 to 1) tu-
mors, respectively. A, Overall survival Curves (5-year overall
survival rate and median survival time of patients with HER2-
FISH positive and negative tumors of 39.1% and 31.1%, re-
spectively, and 28.3 months and 23.6 months, respectively;
log-rank test; p  0.4986). B, Progression-Free survival
Curves (median progression-free survival times of 14.1
month and 10.6 months in those with the positive and neg-
ative HER2-FISH results, respectively, log-rank test; p  0.8843).
TABLE 2. Multivariate Analysis for Survival of the 68 Patients
Factors
Overall Survival Progression-free Survival
HR 95% CI p HR 95% CI p
HER2-FISH (positive vs. negative) 2.568 1.117–5.903 0.0264 2.283 1.005–5.189 0.0487
HER2-IHC (positive vs. negative) 0.614 0.240–1.571 0.3084 0.917 0.344–2.443 0.8620
Nodal metastasis (N0–2 vs. N3) 0.567 0.235–1.368 0.2066 0.750 0.312–1.802 0.5201
Age (70 vs. 70) 0.359 0.147–0.881 0.0253 0.443 0.181–1.084 0.0745
Histology (Sq vs. others) 0.477 0.198–1.146 0.0979 0.638 0.267–1.524 0.3118
PS (0 vs. others)a 0.835 0.365–1.913 0.6701 0.903 0.390–2.090 0.8118
Protocol regimens (#9404 vs. #9707)b 0.638 0.257–1.581 0.3315 0.700 0.276–1.775 0.4525
Cox hazard model was applied.
a Eastern Cooperative Oncology Group performance status.
b Combination chemotherapy with concurrent thoracic irradiation (cisplatin and 5-fluorouracil regimen in the Okayama Lung Cancer
Study Group Protocol 9404) and cisplatin and docetaxel regimen in the Okayama Lung Cancer Study Group Protocol 9707).
Sq, squamous cell carcinoma; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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low-risk breast cancers.11 These results indicate that the FISH
results are more useful for predicting patient outcome than IHC
results. Nevertheless, our data need to be interpreted with cau-
tion, because the definition of HER2-FISH positivity is still
undetermined. Lung cancer is likely to express lower levels of
HER2 protein than breast cancer.3 Because there is controversy
as to whether the criteria for HER2 positivity in breast cancer
can be applied to lung cancer, a new definition should be
established for NSCLC. We conducted the FISH analysis early
after the completion of the original phase II trials, according to
the criteria by Hirsch et al15 that seems simpler than the other
existing scoring methods for HER2-FISH in lung cancer more
recently published.18,21 Thus, we need to further clarify which of
the criteria would be better in lung cancer. A validation analysis
in a large cohort of lung cancer patients is also strongly recom-
mended to determine whether our definition is appropriate for
predicting outcome in LA-NSCLC.
In our study, there was no association between HER2
status and objective response to the combination therapy.
This discordance in results for response and survival may
simply be attributable to the small sample size, inconsistent
response criteria, and definition for HER2-positive results. As
another explanation, disease stabilization as well as objective
response would be an indicator of a benefit from this com-
bined treatment, as some investigators reported the role of
stable disease achieved by chemotherapy in survival advan-
tage.22 In addition, the better survival after chemoradiother-
apy in the patients with HER2-FISH-positive results may
essentially be attributable to a poor natural history, irrespec-
tive of therapeutic efficacy. Several studies in breast cancer
have shown that the HER2 status would represent a distinct
tumor group with a more aggressive natural history and a
worse outcome.23 Therefore, determining whether NSCLC
with HER2-FISH-positive status has a poorer prognosis re-
gardless of therapy awaits further carefully designed popula-
tion studies.
As a limitation, we obtained in this study the limited
information about the patient demographics from the case report
forms of the original phase II trials. Therefore, our results from
the multivariate analyses should be cautiously interpreted be-
cause we failed to include several important clinical factors (i.e.,
smoking history) to be adjusted in the model.
In conclusion, we first showed that HER2-FISH status is
correlated with the outcome of LA-NSCLC patients after first-
line concurrent chemoradiotherapy. This observation supports
the notion that LA-NSCLC patients constitute a heterogeneous
population with various clinical outcomes that would potentially
be stratified by HER2-FISH status, although validation studies
are needed in a different LA-NSCLC cohort to confirm our data.
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